lexgenLex GeneticaLex Genetica3034-16393034-1647МГЮА10.17803/lexgen-2025-4-4-110-121lexgen-91Research ArticleLex Genetica: экспертный комментарийLex Genetica: Expert CommentaryПредотвращение искажения результатов научных исследований в области биологической психиатрииPrevention of Research Results Distortion in the Field of Biological PsychiatryЗахароваН. В.ZakharovaN. V.

Наталья В. Захарова, кандидат медицинских наук, ведущий научный сотрудник Института персонализированной психиатрии и неврологии; ведущий эксперт

Санкт-Петербург

Самара

Natalia V. Zakharova, Candidate Science (Medicine), Leading Researcher, Institute of Personalized Psychiatry and Neurology; Leading Expert

 Saint Petersburg

Samara

nvzaharova@msal.ruБочароваМ.BocharovaM.

Мария Бочарова, факультет психологической медицины Института психиатрии, психологии и нейронаук

Лондон

Mariia Bocharova, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience

London

ГайдукА. Я.GaydukA. Ya.

Арсений Я. Гайдук, и. о. директора Научно-образовательного центра нейропсихиатрии

Самара

Arseniy Ya. Gayduk, Acting Director of the Scientific and Educational Center for Neuropsychiatry

 Samara

Национальный медицинский исследовательский центр психиатрии и неврологии имени В.П. Бехтерева (НМИЦ ПН им. В.П. Бехтерева; Самарский государственный медицинский университет (СамГМУ)Bekhterev National Medical Research Center for Psychiatry and Neurology; Samara State Medical UniversityКоролевский колледж ЛондонаKing’s College LondonСамарский государственный медицинский университет (СамГМУ)Samara State Medical University20250601202644110121Copyright © Захарова Н.В., Бочарова М., Гайдук А.Я., 20252025Захарова Н.В., Бочарова М., Гайдук А.Я.Zakharova N.V., Bocharova M., Gayduk A.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://lexgen.msal.ru/jour/article/view/91

Меры по предотвращению искажений в научных исследованиях персонализированной психиатрии включают строгий контроль данных, прозрачность всех процедур (начиная от получения подписанного информированного согласия от пациента с психическими отклонениями до администрирования процессов передачи информации между подразделениями одного или нескольких научных учреждений), соблюдение этических норм и многоуровневую систему проверок и аудита. Специфика персонализированной психиатрии, основанной на индивидуальных данных (генетика, биомаркеры, данные об образе жизни), требует особого внимания к целостности и достоверности информации. Представлен обзор зарубежного опыта и предложений по предотвращению возможных искажений результатов медико-биологических исследований ментальных функций. Искажения могут происходить на разных этапах исследований – от некачественного сбора и систематизации материала, ошибок при внесении данных в таблицы (вследствие невнимательности или при отсутствии автоматизации этого процесса) до намеренных изменений результатов с техническими манипуляциями изображений микроскопии.

Measures to prevent bias in personalized psychiatry research include strict data control, transparency of all procedures (from obtaining signed informed consent from patients with mental disorders to administering information transfer processes between departments within one or more research institutions), adherence to ethical standards, and a multi-level system of checks and audits. The specific nature of personalized psychiatry, based on individual data (genetics, biomarkers, lifestyle data), requires special attention to the integrity and reliability of the information. This article presents a review of international experience and, on this basis, advances proposals for preventing potential bias in the results of medical and biological research on mental functions. Distortions can occur at various stages of research – from poor collection and systematization of material, errors in entering data into tables (due to carelessness or lack of automation of this process) to intentional changes in the results through technical manipulation of microscopy images.

биоэтикапсихиатрияискажение исследованийбиомедицинские исследованиbioethicspsychiatryresearch distortionbiomedical researchРабота частично выполнена в рамках проекта «Оценка рисков метаболических нарушений с учетом показателей системного воспаления у пациентов с психическими расстройствами», ЕГИСУ НИОКТР рег. № XSOZ 2024 0012.This research was partially conducted as part of the project «Assessing the Risks of Metabolic Disorders Taking into Account Indicators of Systemic Inflammation in Patients with Mental Disorders», EGISU NIOKTR reg. No. XSOZ 2024 0012.ReferencesBeasley, R., Clayton, T., Crane, J., Von Mutius, E., Lai, C. K., Montefort, S., Stewart, A. (2008). Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6–7 years: analysis from Phase Three of the ISAAC programme. The Lancet, 372(9643), 1039–1048. https://doi.org/10.1016/S0140-6736(08)61445-2Beasley, R., Clayton, T., Crane, J., Von Mutius, E., Lai, C. K., Montefort, S., Stewart, A. (2008). Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6–7 years: analysis from Phase Three of the ISAAC programme. The Lancet, 372(9643), 1039–1048. https://doi.org/10.1016/S0140-6736(08)61445-2Bialas, A.R., Presumey, J., Das, A., van der Poel, C.E., Lapchak, P.H., Mesin, L., ... Carroll, M.C. (2017). Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature, 546(7659), 539–543. https://doi.org/10.1038/nature22821Bialas, A.R., Presumey, J., Das, A., van der Poel, C.E., Lapchak, P.H., Mesin, L., ... Carroll, M.C. (2017). Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature, 546(7659), 539–543. https://doi.org/10.1038/nature22821Bousman, C.A., Bengesser, S.A., Aitchison, K.J., Amare, A.T., Aschauer, H., Baune, B.T., ... Müller, D.J. (2021). Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry, 54(01), 5–17. https://doi.org/10.1055/a-1288-1061Bousman, C.A., Bengesser, S.A., Aitchison, K.J., Amare, A.T., Aschauer, H., Baune, B.T., ... Müller, D.J. (2021). Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry, 54(01), 5–17. https://doi.org/10.1055/a-1288-1061Caudle, K.E., Dunnenberger, H.M., Freimuth, R.R., Peterson, J.F., Burlison, J.D., Whirl-Carrillo, M., ... Hoffman, J.M. (2017). Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genetics in Medicine, 19(2), 215–223. https://doi.org/10.1038/gim.2016.87Caudle, K.E., Dunnenberger, H.M., Freimuth, R.R., Peterson, J.F., Burlison, J.D., Whirl-Carrillo, M., ... Hoffman, J.M. (2017). Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genetics in Medicine, 19(2), 215–223. https://doi.org/10.1038/gim.2016.87Chen, P., Li, X.H., Su, Z., Tang, Y.L., Ma, Y., Ng, C.H., Xiang, Y.T. (2022). Characteristics of global retractions of schizophrenia-related publications: A bibliometric analysis. Frontiers in Psychiatry, 13, 937330. https://doi.org/10.3389/fpsyt.2022.937330Chen, P., Li, X.H., Su, Z., Tang, Y.L., Ma, Y., Ng, C.H., Xiang, Y.T. (2022). Characteristics of global retractions of schizophrenia-related publications: A bibliometric analysis. Frontiers in Psychiatry, 13, 937330. https://doi.org/10.3389/fpsyt.2022.937330Doi, N., Hoshi, Y., Itokawa, M., Yoshikawa, T., Ichikawa, T., Arai, M., ... Tachikawa, H. (2012). Paradox of schizophrenia genetics: is a paradigm shift occurring? Behavioral and Brain Functions, 8(1), 28. https://doi.org/10.1186/1744-9081-8-28Doi, N., Hoshi, Y., Itokawa, M., Yoshikawa, T., Ichikawa, T., Arai, M., ... Tachikawa, H. (2012). Paradox of schizophrenia genetics: is a paradigm shift occurring? Behavioral and Brain Functions, 8(1), 28. https://doi.org/10.1186/1744-9081-8-28Eggertson, L. (2010). Lancet retracts 12-year-old article linking autism to MMR vaccines. Canadian Medical Association Journal (CMAJ), 182(4), E199–E200. https://doi.org/10.1503/cmaj.109-3179Eggertson, L. (2010). Lancet retracts 12-year-old article linking autism to MMR vaccines. Canadian Medical Association Journal (CMAJ), 182(4), E199–E200. https://doi.org/10.1503/cmaj.109-3179George, B., Klijn, A. (2014). Psychosis susceptibility syndrome: an alternative name for schizophrenia. The Lancet Psychiatry, 1(2), 110–111. https://doi.org/10.1016/S2215-0366(14)70249-4George, B., Klijn, A. (2014). Psychosis susceptibility syndrome: an alternative name for schizophrenia. The Lancet Psychiatry, 1(2), 110–111. https://doi.org/10.1016/S2215-0366(14)70249-4Harvey, P.D., Heaton, R.K., Carpenter Jr, W.T., Green, M.F., Gold, J.M., Schoenbaum, M. (2012). Diagnosis of schizophrenia: consistency across information sources and stability of the condition. Schizophrenia Research, 140(1-3), 9–14. https://doi.org/10.1016/j.schres.2012.03.026Harvey, P.D., Heaton, R.K., Carpenter Jr, W.T., Green, M.F., Gold, J.M., Schoenbaum, M. (2012). Diagnosis of schizophrenia: consistency across information sources and stability of the condition. Schizophrenia Research, 140(1-3), 9–14. https://doi.org/10.1016/j.schres.2012.03.026Janardhanan, A., Sadanand, A., Vanisree, A.J. (2017). Retracted Paper-Nardostachys jatamansi Targets BDNF-TrkB to Alleviate Ketamine-Induced Schizophrenia-Like Symptoms in Rats. Neuropsychobiology, 74(2), 104–114. https://doi.org/10.1159/000454985Janardhanan, A., Sadanand, A., Vanisree, A.J. (2017). Retracted Paper-Nardostachys jatamansi Targets BDNF-TrkB to Alleviate Ketamine-Induced Schizophrenia-Like Symptoms in Rats. Neuropsychobiology, 74(2), 104–114. https://doi.org/10.1159/000454985Khan, H., Gupta, P., Zimba, O., Gupta, L. (2022). Bibliometric and altmetric analysis of retracted articles on COVID-19. Journal of Korean Medical Scienc e, 37(6), е44. https://doi.org/10.3346/jkms.2022.37.e44Khan, H., Gupta, P., Zimba, O., Gupta, L. (2022). Bibliometric and altmetric analysis of retracted articles on COVID-19. Journal of Korean Medical Scienc e, 37(6), е44. https://doi.org/10.3346/jkms.2022.37.e44Kopylov, A.T., Stepanov, A.A., Butkova, T.V., Malsagova, K.A., Zakharova, N.V., Kostyuk, G.P., ... Kaysheva, A.L. (2023). Consolidation of metabolomic, proteomic, and GWAS data in connective model of schizophrenia. Scientific Reports, 13(1), 2139. https://doi.org/10.1038/s41598-023-29117-7Kopylov, A.T., Stepanov, A.A., Butkova, T.V., Malsagova, K.A., Zakharova, N.V., Kostyuk, G.P., ... Kaysheva, A.L. (2023). Consolidation of metabolomic, proteomic, and GWAS data in connective model of schizophrenia. Scientific Reports, 13(1), 2139. https://doi.org/10.1038/s41598-023-29117-7Marder, S.R., Galderisi, S. (2017). The current conceptualization of negative symptoms in schizophrenia. World Psychiatry, 16(1), 14–24. https://doi.org/10.1002/wps.20385Marder, S.R., Galderisi, S. (2017). The current conceptualization of negative symptoms in schizophrenia. World Psychiatry, 16(1), 14–24. https://doi.org/10.1002/wps.20385McCambridge, J., Witton, J., Elbourne, D.R. (2014). Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. Journal of Clinical Epidemiology, 67(3), 267–277. https://doi.org/10.1016/j.jclinepi.2013.08.015McCambridge, J., Witton, J., Elbourne, D.R. (2014). Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. Journal of Clinical Epidemiology, 67(3), 267–277. https://doi.org/10.1016/j.jclinepi.2013.08.015Nair, S., Yean, C., Yoo, J., Leff, J., Delphin, E., Adams, D.C. (2020). Reasons for article retraction in anesthesiology: a comprehensive analysis. Canadian Journal of Anesthesia/Journal Canadien d'Anesthésie, 67(1), 57–63. https://doi.org/10.1007/s12630-019-01508-3Nair, S., Yean, C., Yoo, J., Leff, J., Delphin, E., Adams, D.C. (2020). Reasons for article retraction in anesthesiology: a comprehensive analysis. Canadian Journal of Anesthesia/Journal Canadien d'Anesthésie, 67(1), 57–63. https://doi.org/10.1007/s12630-019-01508-3Nakagami, E., Hoe, M., Brekke, J.S. (2010). The prospective relationships among intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia. Schizophrenia Bulletin, 36(5), 935–948. https://doi.org/10.1093/schbul/sbq043Nakagami, E., Hoe, M., Brekke, J.S. (2010). The prospective relationships among intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia. Schizophrenia Bulletin, 36(5), 935–948. https://doi.org/10.1093/schbul/sbq043Nakagami, E., Xie, B., Hoe, M., Brekke, J.S. (2008). Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects. Schizophrenia Research, 105(1-3), 95–104. https://doi.org/10.1016/j.schres.2008.06.015Nakagami, E., Xie, B., Hoe, M., Brekke, J.S. (2008). Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects. Schizophrenia Research, 105(1-3), 95–104. https://doi.org/10.1016/j.schres.2008.06.015Nosek, B.A., Lakens, D. (2014). Registered reports. Social Psychology, 45(3), 137–141. https://doi.org/10.1027/1864-9335/a000192Nosek, B.A., Lakens, D. (2014). Registered reports. Social Psychology, 45(3), 137–141. https://doi.org/10.1027/1864-9335/a000192Ren, Z., Wang, H., Feng, B., Gu, C., Ma, Y., Chen, H., ... Liu, L. (2014). A cross-sectional study on perception of stigma by Chinese schizophrenia patients. Neuropsychiatric Disease and Treatment, 10, 535–540. https://doi.org/10.2147/NDT.S54115Ren, Z., Wang, H., Feng, B., Gu, C., Ma, Y., Chen, H., ... Liu, L. (2014). A cross-sectional study on perception of stigma by Chinese schizophrenia patients. Neuropsychiatric Disease and Treatment, 10, 535–540. https://doi.org/10.2147/NDT.S54115Resnik, D.B., Stewart Jr, C.N. (2012). Misconduct versus honest error and scientific disagreement. Accountability in Research, 19(1), 56–63. https://doi.org/10.1080/08989621.2012.650948Resnik, D.B., Stewart Jr, C.N. (2012). Misconduct versus honest error and scientific disagreement. Accountability in Research, 19(1), 56–63. https://doi.org/10.1080/08989621.2012.650948Van Os, J. (2009). A salience dysregulation syndrome. The British Journal of Psychiatry, 194(2), 101–103. https://doi.org/10.1192/bjp.bp.108.054254Van Os, J. (2009). A salience dysregulation syndrome. The British Journal of Psychiatry, 194(2), 101–103. https://doi.org/10.1192/bjp.bp.108.054254Vuong, Q.H. (2020). Reform retractions to make them more transparent. Nature, 582(7811), 149–149. https://doi.org/10.1038/d41586-020-01694-xVuong, Q.H. (2020). Reform retractions to make them more transparent. Nature, 582(7811), 149–149. https://doi.org/10.1038/d41586-020-01694-xYang, H., Li, J., Ji, A., Hu, L., Zhang, X., Liu, L., ... Nie, S. (2020). Retraction “Methylation of the MAOA promoter is associated with schizophrenia”. Annals of Translational Medicine, 8(22), 1555. https://doi.org/10.21037/atm-2020-42Yang, H., Li, J., Ji, A., Hu, L., Zhang, X., Liu, L., ... Nie, S. (2020). Retraction “Methylation of the MAOA promoter is associated with schizophrenia”. Annals of Translational Medicine, 8(22), 1555. https://doi.org/10.21037/atm-2020-42Yoshida, K., Müller, D.J. (2019). Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. Molecular Neuropsychiatry, 5(Suppl. 1), 1–26. https://doi.org/10.1159/000492332Yoshida, K., Müller, D.J. (2019). Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. Molecular Neuropsychiatry, 5(Suppl. 1), 1–26. https://doi.org/10.1159/000492332

The authors declare that there are no conflicts of interest present.